Published in final edited form as:

Chem Res Toxicol. 2010 January 18; 23(1): 118–133. doi:10.1021/tx900312e.

Exocyclic Deoxyadenosine Adducts of 1,2,3,4-Diepoxybutane: Synthesis, Structural Elucidation, and Mechanistic Studies

Uthpala Seneviratne^{†,‡}, Sergey Antsyovich^{†,§}, Melissa Goggin[†], Danae Quirk Dorr^{†,Ω}, Rebecca Guza[†], Adam Moser[‡], Carrie Thompson[†], Darrin M. York[‡], and Natalia Tretyakova^{†,*}

[†]Department of Medicinal Chemistry and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455

[‡]Department of Chemistry, University of Minnesota, Minneapolis, MN 55455

Abstract

1,2,3,4-Diepoxybutane (DEB) is considered the ultimate carcinogenic metabolite of 1,3-butadiene, an important industrial chemical and environmental pollutant present in urban air. Although it preferentially modifies guanine within DNA, DEB induces a large number of A → T transversions, suggesting that it forms strongly mispairing lesions at adenine nucleobases. We now report the discovery of three potentially mispairing exocyclic adenine lesions of DEB: *N*⁶,*N*⁶-(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (compound **2**), *1,N*⁶-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (compound **3**), and *1,N*⁶-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (compound **4**). The structures and stereochemistry of the novel DEB-dA adducts were determined by a combination of UV and NMR spectroscopy, tandem mass spectrometry, and independent synthesis. We found that synthetic *N*⁶-(2-hydroxy-3,4-epoxybut-1-yl)-2'-deoxyadenosine (compound **1**) representing the product of *N*⁶-adenine alkylation by DEB spontaneously cyclizes to form **3** under aqueous conditions or **2** under anhydrous conditions in the presence of organic base. Compound **3** can be interconverted with **4** by a reversible unimolecular pericyclic reaction favoring **4** as a more thermodynamically stable product. Both **3** and **4** are present in double stranded DNA treated with DEB *in vitro* and in liver DNA of laboratory mice exposed to 1,3-butadiene by inhalation. We propose that in DNA under physiological conditions, DEB alkylates the N-1 position of adenine in DNA to form *N1*-(2-hydroxy-3,4-epoxybut-1-yl)-adenine adducts, which undergo an S_N2-type intramolecular nucleophilic substitution and rearrangement to give **3** (minor) and **4** (major). Formation of exocyclic DEB-adenine lesions following exposure to 1,3-butadiene provides a possible mechanism of mutagenesis at the A:T base pairs.

Introduction

Exocyclic nucleobase adducts are among the most important types of DNA damage because of their ability to exert significant biological effects (1-3). These lesions are characterized by considerable changes of the molecular size/shape and hydrogen bonding characteristics of the parent nucleobase, leading to mispairing during DNA synthesis (4-9). For example, *1,N*⁶-etheno-deoxyadenosine adducts induced by vinyl chloride preferentially adopt the *syn* conformation about the glycosidic bond, forming a Hoogsteen base pair with guanine or cytosine instead of the normal adenine partner, thymine (4,10).

One prominent *bis*-electrophile capable of inducing exocyclic nucleobase lesions is 1,2,3,4-diepoxybutane (DEB), the proposed ultimate carcinogenic metabolite of 1,3-butadiene (BD) (11). 1,3-Butadiene is a known animal and human carcinogen found in automobile exhaust and

¹**Abbreviations** in cigarette smoke (12,13). All three possible stereoisomers of DEB: *S,S*, *R,R*, and *meso*, are

1	<i>N</i> ⁶ -(2-hydroxy-3,4-epoxybut-1-yl)-2'-deoxyadenosine (<i>N</i> ⁶ -HEB-dA)
2	<i>N</i> ⁶ , <i>N</i> ⁶ -(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (<i>N</i> ⁶ , <i>N</i> ⁶ -DHB-dA)
3	1, <i>N</i> ⁶ -(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1, <i>N</i> ⁶ - γ HMHP-dA)
4	1, <i>N</i> ⁶ -(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (1, <i>N</i> ⁶ - α HMHP-dA)
BCNU	1,3-bis(2-chloroethyl)-1-nitroso-urea
bis-N7G-BD	4-bis-(guan-7-yl)-2,3-butanediol
BD	1,3-butadiene
BzNH₂	benzylamine
dA	2'-deoxyadenosine
DEB	1,2,3,4-diepoxybutane
DIPEA	<i>N,N</i> -diisopropylethyl amine
DFT	density functional theory
DMSO	dimethylsulphoxide
dR	2'-deoxyribose
EtOH	Ethanol
Fmoc	9-fluorenylmethoxycarbonyl
gCOSY	¹ H- ¹ H gradient Correlation Spectroscopy
gHMBC	gradient Heteronuclear Multiple Bond Correlation
gHMQC	gradient Heteronuclear Multiple Quantum Correlation
HEB	2-hydroxy-3,4-epoxybut-1-yl
HOMO	Highest Occupied Molecular Orbital
HPLC-ESI-MS	high pressure liquid chromatography-electrospray ionization mass spectrometry
HSQC	Heteronuclear Single Quantum Correlation
mCPBA	m-chloroperoxybenzoic acid
MeOH	Methanol
N7G-N1A-BD	1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol
NOESY	Nuclear Overhauser Effect Spectroscopy
PyBOP	benzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate
SPE	Solid phase extraction
THF	tetrahydrofuran
TMS-CN	Trimethylsilyl cyanide
TOCSY	Total Correlation Spectroscopy

* Corresponding author: Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware St. S.E., Minneapolis, MN 55455. Telephone: (612) 626-3432, Fax: (612) 626-5135, treti001@umn.edu

† Current address: Department of Chemistry, Moscow State University, Moscow, Russia

‡ Current address: Department of Chemistry, Minnesota State University, Mankato, MN

Supporting Information Available: kinetics data for cyclization and rearrangement experiments, NMR data tables, molecular modeling results, and crystallography data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

generated metabolically (14). Although DEB is a relatively minor metabolite of BD (laboratory mice exposed to 62.5 ppm BD for 10 days contain ~ 247 pmol DEB/g blood (15)), experimental evidence suggests that it is responsible for many of the adverse effects of BD. DEB is 50–100 fold more genotoxic and mutagenic in human cells than its monoepoxide analogues, 3,4-epoxy-1-butene (EB) and 3,4-epoxy-1,2-butanediol (EBD) (16,17). Efficient metabolism of BD to DEB in target tissues of laboratory mice is thought to cause the increased susceptibility of this species to BD carcinogenesis (18).

The adverse biological effects of DEB have been attributed to its ability to cross-link cellular biomolecules. Initial alkylation of adenine and guanine bases in DNA by DEB produces 2-hydroxy-3,4-epoxybut-1-yl (HEB) lesions, which contain an inherently reactive oxirane group and can alkylate neighboring nucleobases within the DNA duplex to form DNA-DNA cross links, namely, 1,4-*bis*-(guan-7-yl)-2,3-butanediol (*bis*-N7G-BD) and 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD) (19,20). The *S,S* isomer of DEB produces the highest number of interstrand DNA-DNA cross-links (21) and is the most cytotoxic (22,23) and mutagenic (24). Alternatively, the 3,4-epoxy group of the HEB adducts can be subject to nucleophilic attack by another site within the same DNA nucleobase, giving rise to fused ring structures (25-27).

The documented ability of DEB to induce large numbers of A → T transversion mutations (28,29) has led us to hypothesize that it forms strongly mispairing exocyclic lesions at adenine nucleobases within DNA. This hypothesis was supported by our previous work with synthetic DNA oligonucleotides containing site specific *N*⁶-(2-hydroxy-3,4-epoxybut-1-yl) deoxyadenosine adducts (*N*⁶-HEB-dA, **1** in Chart 1) (30). If left in an aqueous solution at room temperature (pH 7.2), **1** underwent spontaneous cyclization to form previously unidentified DEB-dA lesions (see Supporting Information S-1). Another isomer of the exocyclic DEB-dA species was formed as a side product during the synthesis of compound **1** (by reacting 6-chloropurine deoxyriboside with 1-amino-2-hydroxy-3,4-epoxybutane under basic, anhydrous conditions) (30). In the present work, we employed a combination of UV and NMR spectroscopy, tandem mass spectrometry, independent synthesis, DFT calculations, and kinetic analyses to identify the chemical structures of these novel DEB-DNA lesions and to establish the mechanism of their formation.

Materials and Methods

2'-Deoxyinosine was obtained from Berry & Associates, Inc. (Dexter, MI). ¹⁵N₅-dA was purchased from Spectra Stable Isotopes, Div. of Spectra Gases Inc. (Columbia, MD). *d,l* DEB was obtained from the NCI Chemical Carcinogen Repository, and the individual stereoisomers of DEB were prepared as described previously (21). All other chemicals and enzymes were purchased from Sigma-Aldrich Chemical Company (Milwaukee, WI).

Instrumentation

NMR spectra were acquired with a Varian Inova 600 MHz, 800 MHz spectrometer (Varian Inc., Palo Alto, CA) and a Bruker Advance 700 MHz instrument (Bruker BioSpin, Billerica, MA) using DMSO-*d*₆ as the solvent. UV spectrophotometry was performed on a Beckman DU-7400 instrument (Beckman, Fullerton, CA). Optical rotation measurements were performed with Rudolph Autopol III automatic polarimeter at 589 nm (Rudolph Research, Flanders, NJ), and HRMS data were obtained using a Bruker Bio-TOF II instrument.

HPLC-UV Analyses

HPLC was carried out with an Agilent Technologies model 1100 HPLC system equipped with a photodiode array UV detector (Wilmington, DE). Unless specified otherwise, UV absorbance was monitored at 254 nm. HPLC columns and solvent elution systems were as follows:

System 1—A semi-preparative Zorbax Eclipse XDB-C18 (25 cm × 9.4 mm, 5 μm) column was eluted with a linear gradient of acetonitrile (B) in water (A) at a flow rate of 3 mL/min. Solvent composition was changed from 5% to 10.3% B in 35 minutes, then further to 90% B in 2 minutes. This system was used for isolation of exocyclic DEB-dA adducts (compounds **1** and **2**) and the corresponding free bases. To separate **2a** from **2b**, the same column with an isocratic elution of 3% acetonitrile in water was used.

System 2—A preparative silica Whatman Particil 10 (50 cm × 9.4 mm, 10 μm) column was eluted isocratically with 0.5% methanol in chloroform at a flow rate of 5 mL/min. This system was used to separate diastereomers of *N*-Fmoc-1-amino-2-hydroxy-3,4-epoxybutanes (compounds **5a**, **5b**, **5c** and **5d**).

System 3—A 100 mm × 3 mm Thermo Hypersil Hypercarb column (10 cm × 3 mm, 5 μm particle size, Thermo Fisher Scientific, Inc. Waltham, MA) was eluted with a linear gradient of acetonitrile (B) in 0.05 % acetic acid (A). Solvent composition was changed from 0 to 20 % B in 30 min. The column was eluted at a flow rate of 0.5 mL/min. This system was used for separation of **3** and **4** and the corresponding free bases.

Synthesis of *N*-Fmoc-1-Amino-2-hydroxy-3,4-epoxybutane, **5a-5d** (Scheme 4)

Racemic 1-aminobut-3-ene-2-ol was prepared from acrolein as described previously (31) and separated by diastereomeric resolution following derivatization with sodium [(*1R*)-(endo, *anti*)]-(+)-3-Bromocamphor-8-sulfonic acid ammonium salt (32,33), followed by Fmoc protection and epoxidation in the presence of MCPBA (30). Individual stereoisomers of the amino epoxide were isolated by preparative HPLC on a silica column (HPLC System 2). **5a**, [α]_D²⁵ +4.0 (in CHCl₃), ee = 100%; **5b**, [α]_D²⁵ -5.7 (in CHCl₃), ee = 100%; **5c**, [α]_D²⁵ -3.4 (in CHCl₃), ee = 92.5% and **5d**, [α]_D²⁵ +3.9 (in CHCl₃), ee = 84.2%.

Synthesis of *N*⁶,*N*⁶-DHB-dA (Scheme 1 and Chart 1)

S,S, *R,R*, and *meso* *N*⁶,*N*⁶-DHB-dA (compounds **2a-c** in Chart 1) were obtained by coupling commercial 6-chloropurine-2'-deoxyriboside with *S,S*, *R,R*, or *meso* 1-amino-2-hydroxy-3,4-epoxybutane, respectively (Scheme 1) (30). 6-Chloropurine-2'-deoxyriboside (1.45 mg, 5.36 μmol) was dissolved in DIPEA (18.7 μL), and *N*-Fmoc-1-amino-2-hydroxy-3,4-epoxybutane (6.95 mg, 21.4 μmol) dissolved in DMSO (200 μL) was added. The reaction mixture was incubated at 37 °C for 2 days under Ar atmosphere. The reaction products were diluted with water, filtered, and separated using HPLC system 1. Under these conditions, *S,S* and *R,R* *N*⁶,*N*⁶-DHB-dA (compounds **2a** and **2b**) eluted at 15.4 min, while *meso* *N*⁶,*N*⁶-DHB-dA (compound **2c**) was observed as a peak at 16.7 min (2.95 mg, 8.73 μmol, 40.8 %). Compounds **2a** and **2b** were resolved with a different HPLC system (3% ACN in water): **2a**, *t*_R, 55.1 min (1.59 mg, 22.0 % yield), and **2b**, *t*_R, 56.6 min (1.74 mg, 24.0 % yield). UV (water): λ_{max} = 274 nm (Figure 1, left), ESI⁺-MS *m/z* 338.3 [M+H]⁺; MS/MS *m/z* 338.3 → 222.2 [M+2H-dR]⁺; MS³ *m/z* 338.3 → *m/z* 222.2 → *m/z* 136.0 [Ade+H]⁺, 147.6 [Ade-CH₂+H]⁺, 185.6 [M+2H-dR-2H₂O]⁺, 204.0 [M+2H-dR-H₂O]⁺ (Figure 1, right panel).

¹H NMR (DMSO-*d*₆), compound **2a** (*S,S* *N*⁶,*N*⁶-DHB-dA): 8.32 (s, 1H, *H*-8); 8.18 (s, 1H, *H*-2); 6.35 (t, 1H, *H*-1', *J*_{vic}=6.96 Hz); 5.30 (d, 1H, CHOH-3', *J*_{vic}=3.66 Hz); 5.22 (t, 1H, CHOH-5', *J*_{vic}=5.50 Hz); 5.19 (bs, 1H, CHOH^β); 5.17 (bs, 1H, CHOH^γ); 4.40 (bs, 1H, *H*-3'); 4.17 (d, 1H, *H*^α, *J*_{gem}=12.21); 4.09 (m, 1H, *H*^β); 4.01 (m, 2H, *H*^α, *H*^γ); 3.87 (d, 1H, *H*-4', *J*_{vic}

= 2.69 Hz); 3.68 (m, 1H, H^δ); 3.62 (m, 2H, H^δ , $H-5'$); 3.51 (m, 1H, $H-5'$); 2.69 (q, 1H, $H-2'$); 2.26 (dq, 1H, $H-2'$, $J_{\text{gem}} = 13.18$ Hz).

^1H NMR (DMSO- d_6), compound **2b** (*R,R* N^6,N^6 -DHB-dA): 8.32 (s, 1H, $H-8$); 8.18 (s, 1H, $H-2$); 6.35 (t, 1H, $H-1'$, $J_{\text{vic}}=6.84$); 5.22 (bs, 4H, OH-groups); 4.40 (q, 1H, $H-3'$, $J=2.85$); 4.17 (bd, 1H, H^α , $J=12.6$); 4.10 (bs, 1H, H^β); 4.02 (bs, 1H, H^α); 4.00 (bs, 1H, H^γ); 3.87 (q, 1H, $H-4'$, $J=4.2$); 3.69 (bd, 1H, H^δ); 3.63 (m, 1H, H^δ); 3.61 (m, 1H, $H-5'$); 3.51 (dd, 1H, $H-5'$, $J_1=11.70$, $J_2=4.50$); 2.68 (m, 1H, $H-2'$); 2.25 (dq, 1H, $H-2'$, $J_1=13.20$, $J_2=3.20$).

^1H NMR (DMSO- d_6), compound **2c** (*S,R* and *R,S* N^6,N^6 -DHB-dA): 8.33 (s, 1H, $H-8$); 8.19 (s, 1H, $H-2$); 6.36 (t, 1H, $H-1'$, $J_{\text{vic}}=6.9$ Hz); 5.31 (d, 1H, $\text{CHOH}-3'$, $J_{\text{vic}}=4.2$); 5.21 (t, 1H, $\text{CHOH}-5'$, $J_{\text{vic}}=5.7$ Hz); 5.03 (d, 1H, CHOH^β , $J_{\text{vic}}=3.7$ Hz); 4.96 (bs, 1H, CHOH'); 4.40 (m, 1H, $H-3'$, $J_1=5.7$; $J=2.9$ Hz); 4.21 (d, 1H, H^α , $J_{\text{gem}} = 12.0$ Hz); 4.17 (bs, 1H, H^β); 4.13 (bs, 1H, H^γ); 3.91 (d, 1H, H^α , $J_{\text{gem}}=10.2$ Hz); 3.88 (q, 1H, $H-4'$, $J_{\text{vic}}=4.2$ Hz); 3.72 (d, 1H, H^δ , $J_{\text{gem}}=12.0$ Hz); 3.61 (m, 2H, $H-5'$, H^δ , $J_{\text{gem}} = 11.71$ Hz; $J_{\text{vic}} = 4.4$ Hz); 2.70 (m, 1H, $H-2'$, $J_{\text{gem}} = 13.2$ Hz; $J_{\text{vic}} = 6.3$ Hz); 2.26 (m, 1H, $H-2'$, $J_{\text{gem}} = 13.2$ Hz; $J_{\text{vic}} = 6.6$ Hz).

Computational methods

Density-functional electronic structure calculations were performed according to the protocol used in the QCRNA database (34). The calculations included geometry optimization, vibrational frequency analysis, and solvation energy corrections. Kohn-Sham density-functional calculations were performed using the hybrid exchange functional of Becke (35) and the Lee, Yang, and Parr correlation functional (36) (B3LYP) as implemented in the Gaussian03 suite of programs (see http://www.gaussian.com/citation_g03.htm). Relaxed potential energy surface scans around the C-N torsion angle were performed at the B3LYP/6-31+G(d,p) level with the torsion constrain set in 15 degree intervals, with additional unconstrained (fully optimized) points at the minima.

Molecular orbitals for the axial, equatorial, and pucker transition state structures of **2a-base** were calculated. All structures showed at least 7 orbitals with significant density above and below the C-N sigma bond. Supporting information S-12A and S-12B show a top view and side view of two molecular orbitals (HOMO-2 and HOMO-20) of compound **2a-base** in an equatorial-like conformation.

Independent synthesis of compounds **2a**, **2b** and **2c** (Scheme 3)

3*R,4R* pyrrolidine-2,3-diol (125 mg, synthesized as described previously)(37,38) was coupled with 2'-deoxyinosine (250 mg) in the presence of DMSO (5 mL), DIPEA (210 μL), and PyBOP (656 mg) (55 °C for 3 days). The reaction mixtures were resolved by flash chromatography (CH_2Cl_2 : MeOH solvent gradient using a Silica column) and reversed phase HPLC (system 1) to give optically pure (*R,R*)- N^6,N^6 -DHB dA, $[\alpha]^{25}_{\text{D}} +43.0$ (in MeOH) (**2a**) in 72% yield. The same synthetic route starting with *L*-tartaric acid and *meso*-tartaric acid was followed to obtain the optically pure (*S,S*)- N^6,N^6 -DHB dA, $[\alpha]^{25}_{\text{D}} -42.8$ (in MeOH) (**2b**) and *meso* N^6,N^6 -DHB dA, $[\alpha]^{25}_{\text{D}} -19.4$ (in MeOH) (**2c**) respectively.

Synthesis of *R,R* (**1a**), *R,S* (**1b**), *S,S* (**1c**), *S,R* (**1d**) N^6 -HEB-dA

5*a* - 5*d* (15 mg (37,38)) was coupled with 2'-deoxyinosine (15 mg) in the presence of DMSO (1mL), DIPEA (50 μL), and PyBOP (30 mg) (37 °C for 5 days) separately. The reaction mixtures were resolved by reversed phase HPLC (system 1) to give (*R,R*)- N^6 -HEB dA, (**1a**), (*R,S*)- N^6 -HEB dA, (**1b**), (*S,S*)- N^6 -HEB dA, (**1c**), and (*S,R*)- N^6 -HEB dA, (**1d**) separately in 95 % yield.

Synthesis of compound 3 and 4 in Chart 1

Racemic *N*⁶-HEB-dA (compound 1 in Chart 1, 1.5 mg) (30) was dissolved in 250 μ L of water and incubated for 15 h at room temperature. Spontaneous cyclization of *N*⁶-HEB-dA produced 3 and 4, which were isolated with HPLC system 3: 3, *t*_R, 12.5 min and 4, *t*_R, 16.8 min (3, 0.87 mg, 2.55 μ mol, 57.3 % yield and 4, 0.57 mg, 1.67 μ mol, 38.0 % yield, ratio of 3:4; 7:3). UV (pH 7) 3 and 4, λ_{max} = 264 nm. Compound 3: ESI⁺-MS *m/z* 338.3 [M+H]⁺, MS² *m/z* 338.3 $\rightarrow$ *m/z* 222.2 [M+2H-dR]⁺; MS³ *m/z* 338.3 $\rightarrow$ *m/z* 222.2 $\rightarrow$ *m/z* 136.0 [Ade+H]⁺, 148.0 [Ade-CH₂+H]⁺, 186.0 [M+2H-dR-2H₂O]⁺. Compound 4: ESI⁺-MS *m/z* 338.3 [M+H]⁺, MS² *m/z* 338.3 $\rightarrow$ *m/z* 222.2 [M+2H-dR]⁺; MS³ *m/z* 338.3 $\rightarrow$ *m/z* 222.2 $\rightarrow$ *m/z* 160.6 [Ade-CCH+H]⁺, 177.5 [Ade-(CH)₂OH+H]⁺, 203.6 [M+2H-dR-H₂O]⁺.

Synthesis of 3a - 3d and 4a - 4d

1a - 1d were dissolved in 250 μ L of water and incubated for 12 h at room temperature. The cyclization products were purified with HPLC system 3. 3a and 4a were obtained from cyclization of 1a, 3b and 4b were obtained from cyclization of 1b, 3c and 4c were obtained from cyclization of 1c, 3d and 4d were obtained from cyclization of 1d with a ratio of 7:3. 3a, *t*_R, 12.5 min, 4a, *t*_R, 16.8 min, 4b, *t*_R, 19.6 min and 3b, *t*_R, 21.7 min, 3c, *t*_R, 12.5 min, 4c, *t*_R, 16.8 min, 4d, *t*_R, 19.6 min and 3d, *t*_R, 21.7 min. The ¹H NMR, NOESY, gCOSY, gHSQC and HMBC data for compounds 3a, 3b, 4a and 4b are presented in Supporting Information S-14 - S-18.

¹⁵N₄-deoxyinosine

¹⁵N₅-deoxyadenosine (10 mg, 80 μ mol) was incubated in the presence of adenosine deaminase (80 units) in 10 mM Tris-HCl, pH 7.4 (0.75 mL) at 37° C for 24 h. HPLC analysis revealed a single peak corresponding to ¹⁵N₅-deoxyinosine. The mixture was filtered through YM-30 Centricon filter to remove any protein and desalted using Waters C18 SPE cartridges (95% yield).

Synthesis of ¹⁵N₄-labeled compound 3 and 4

To a solution of ¹⁵N₄-deoxyinosine (0.026 mmol, 6.5 mg) in DMSO (2.5 mL), PyBOP (0.026 mmol, 13.5 mg), DIPEA (0.11 mmol, 19 μ L), and racemic Fmoc-hydroxy-epoxide (0.022 mmol, 7 mg) was added (39). The mixture was stirred for 3 days at room temperature under nitrogen to give ¹⁵N₄-*N*⁶-HEB-dA. ESI⁺-MS *m/z* 342.3 [M+H]⁺, MS² *m/z* 342.3 $\rightarrow$ *m/z* 226.2 [M+2H-dR]⁺; MS³ *m/z* 342.3 $\rightarrow$ *m/z* 226.2 $\rightarrow$ *m/z* 140.0 [¹⁵N₄-HX+H]⁺, 152.0 [¹⁵N₄-HX-CH₂+H]⁺, 190.0 [M+2H-dR-2H₂O]⁺, 208.0 [M+2H-dR-H₂O]⁺. ¹⁵N₄-*N*⁶-HEB-dA was quantitatively converted to ¹⁵N₄-labeled compounds 3 and 4 by incubating in water overnight, followed by HPLC purification with HPLC system 3. Standard solutions of ¹⁵N₄-labeled 3 and 4 were prepared in water and quantified by UV spectrophotometry.

Forced Dimroth rearrangement of 3a and 4a

Compounds 3a and 4a were separately dissolved in 200 μ L of 0.25 M NaOH solution and kept at room temperature for 1 h, followed by neutralization with 1 M HCl. The reaction mixtures were then heated to 60 °C after the addition of 300 μ L of 95 % EtOH and kept for 4 more hours. About 8 μ L was injected onto a capillary HPLC column for HPLC-ESI⁺-MS/MS analysis.

Neutral thermal hydrolysis

Nucleoside adducts (0.1 mg each) were dissolved in 100 μ L of water and heated for 1 h at 85 °C. The resulting reaction mixtures were separated with HPLC system 1 and 3.

Synthesis of nucleobase adducts via acid hydrolysis of the corresponding nucleosides—Compounds **2a**, **2b**, **2c**, **3** and **4** were dissolved in 0.1 M HCl (250 μ L) and heated for 1 h at 85 °C. The resulting reaction mixtures were neutralized with 0.1 M NaOH and separated by HPLC (System 1 and 3). Compound **2a-base** (Chart 2) was isolated as a peak at 7.7 min (0.62 mg, 2.78 μ mol, 94.0 % yield). Compound **2b-base** was isolated as a peak at 8.1 min (0.62 mg, 2.81 μ mol, 95.0 % yield). *S,R; R,S*-*N*⁶,*N*⁶-(2,3-dihydroxybutan-1,4-diyl)-adenine (**2c-base**, Chart 2) was isolated at 11.7 min (0.65 mg, 2.93 μ mol, 99.0 % yield). Compounds **2a-base**, **2b-base**, and **2c-base** had identical UV and mass spectra. UV (water): λ_{max} 274 nm; ESI⁺-MS m/z 222.2 [M+H]⁺, MS² of m/z 222.2: m/z 147.9 [Ade-CH₂+H]⁺, 160.6 [Ade-CH=CH₂]⁺, 175.6 [Ade-CH₂-CH=CH₂+H]⁺, 185.6 [M+2H-dR-2H₂O]⁺, 203.7 [M+2H-dR-H₂O]⁺.

Compound **3-base** was isolated at 8.4 min. λ_{max} 264 nm, ESI⁺-MS: m/z 222.2 [M+H]⁺, MS² of m/z 222.2: m/z 136.0 [Ade+H]⁺, 148.0 [Ade-CH₂+H]⁺, 186.0 [M+2H-dR-2H₂O]⁺.

Compound **4-base** was isolated at 12.1 min. λ_{max} 264 nm, ESI⁺-MS: m/z 222.2 [M+H]⁺, MS² of m/z 222.2: m/z 160.6 [Ade-CCH+H]⁺, 177.5 [Ade-(CH)₂OH+H]⁺, 203.6 [M+2H-dR-H₂O]⁺.

The ¹H NMR, NOESY, gCOSY, TOCSY, gHMQC and HSQC data for compounds **2a-base**, **2b-base** and **2c-base** are presented in Supporting Information S-8 and S-9.

Oxidation of 1,2-diols with sodium periodate and analysis of oxidation products by HPLC-ESI⁺-MS/MS

Nucleobase adducts **2a-base**, **2b-base**, **2c-base**, **3-base**, and **4-base** (3 nmol aliquots) were dissolved in 15 mM aqueous sodium periodate (30 μ L). Thymidine (0.1 μ g) was added as an internal standard for quantitation. Aliquots (6 μ L) were taken following incubation for 10 min, 1 h, 2 h, 4 h, and 23 h. The reaction was terminated by the addition of glycerol (1 μ L), and the samples were frozen until HPLC-ESI⁺-MS/MS analysis with an Agilent 1100 capillary HPLC-ion trap mass spectrometer system (Agilent Technologies, Inc.; Wilmington, DE). A 250 mm $\times$ 0.5 mm Synergi column, 4 μ m particle size (Phenomenex, Torrance, CA) was eluted with a linear gradient of methanol (B) in 0.05% acetic acid (A). Solvent composition was changed from 0% to 1% B in 6 minutes, then further to 4% B in 11 minutes, and finally to 30% B in 2 minutes. The column was eluted at a flow rate of 12 μ L/min. Oxidation products (dialdehyde derivatives and the corresponding hemiacetals) were detected by HPLC-ESI⁺-MS: dialdehyde at m/z 220.2 [M+H]⁺; MS² m/z 220.2 $\rightarrow$ m/z 202.0 [M+H-H₂O]⁺, and hemiacetal at m/z 238.3 [M+H]⁺; MS² m/z 238.3 $\rightarrow$ m/z 220.2 [M+H-H₂O]⁺ (Supporting information S-2).

Kinetics of cyclization **1a** and **1b** in aqueous medium

Pure compounds **1a** or **1b** were dissolved in water and incubated at 37 °C. The reaction products were monitored by HPLC system 1 (**1a**; $t_{1/2}$ = 58 min and **1b**; $t_{1/2}$ = 58 min, Supporting Information S-19). In a separate experiment, **1a** was dissolved in water, and the formation of **3a** and **4a** were monitored by HPLC (system 3, Supporting Information S-22).

Kinetics of the conversion of **3a** and **4b** in aqueous medium

Purified **3a** and **4a** were incubated in water either at room temperature or at 37 °C, and the rearrangement products were detected by HPLC (Supporting Information S-23).

HPLC-ESI-MS/MS analysis of exocyclic DEB-dA adducts in DEB-treated DNA—Calf thymus DNA (500 μ g aliquots, in 500 μ L water) was treated with increasing amounts of *R,R*, *S,S*, and *meso* DEB (0–1 mM) at 37 °C for 24 hours. DNA was precipitated with cold

ethanol and re-suspended in 500 μ L of water. Following spiking with $^{15}\text{N}_4$ -labeled compounds **3** and **4** (500 fmol, internal standards for mass spectrometry), DNA was digested to deoxynucleosides in the presence of Nuclease P1 (10 U) and alkaline phosphatase (60 U, 37 °C for 1 hour). Samples were filtered through YM-30 Centricon filters to remove proteins prior to solid phase extraction (SPE). Carbograp SPE cartridges (3 mL, Alltech) were prepared by washing with methanol (2×3 mL) and water (2×3 mL). Samples were loaded in water (1 mL), washed with water and 10 % methanol (3 mL each), and eluted with 30 % methanol (3mL). The 30% methanol elutions were concentrated under vacuum, and re-dissolved in 25 μ L of water. About 8 μ L was injected onto a capillary HPLC column for HPLC-ESI⁺-MS/MS analysis. Exocyclic DEB-dA adduct amounts were determined from the relative response ratios (mass spectrometry peak area of exocyclic DEB-dA adduct to mass spectrometry peak area of isotopically labeled internal standard).

HPLC-ESI-MS/MS analysis of exocyclic DEB-dA adducts in tissues of B6C3F1 mice exposed to BD by inhalation—B6C3F1 mice were exposed to 625 ppm butadiene or air (controls) for 2 weeks, and liver DNA was isolated using NuceoBond AXG500 anion exchange cartridges (Macherey-Nagel) (40). DNA purity and amounts were determined by UV spectrophotometry. The A_{260}/A_{280} ratios were 1.7–1.8, confirming minimal protein contamination. DNA (100 μ g) was spiked with $^{15}\text{N}_4$ -labeled compounds **3** and **4** (300 fmol each) and subjected to enzymatic digestion as described above for CT DNA. Samples were filtered through YM-10 Centricon microfilters, purified by SPE as above for CT DNA, dried under vacuum, and dissolved in 25 μ L water. About 8 μ L was injected onto a capillary HPLC column for HPLC-ESI-MS/MS analysis as described above for CT DNA.

Liquid chromatography-mass spectrometry—The majority of HPLC-ESI-MS experiments were performed with an Agilent 1100 capillary HPLC-ion trap mass spectrometer (Agilent Technologies, Inc.; Wilmington, DE). The instrument was operated in the ESI⁺ mode. Target ion abundance value was set to 30,000, the maximum accumulation time was 300 milliseconds, and 4 scans were taken per average. A typical fragmentation amplitude was 0.7 V, with a scan width of 1.2 m/z . Nitrogen was used as a nebulizing (15 psi) and a drying gas (5 L/min, 200 °C). Electrospray ionization was achieved at a spray voltage of 3–3.5 kV.

For analyses of nucleoside reaction mixtures, samples were dissolved in a 1:1 mixture of acetonitrile and 0.1% acetic acid and infused at a flow rate of 10–15 μ L/min using a syringe pump. The mass spectrometer was operated in a full scan mode over the range of m/z 50–350.

Enzymatic digests of DEB-treated DNA and liver DNA from control and butadiene-exposed mice were analyzed with an Agilent 1100 capillary HPLC system (Wilmington, DE) interfaced to a Thermo-Finnigan TSQ Quantum Ultra mass spectrometer (Thermo Fisher Scientific Corp., Waltham, MA). A Phenomenex Synergi (250 $\times$ 0.5 mm, 0.4 μ m) column was eluted with a gradient of 10 mM ammonium formate, pH 4.2 (A) and methanol (B). The solvent composition was kept at 100 % A for 5 min, changed to 6 % B over 1 min, and finally increased linearly to 30 % B over 10 min. Under these conditions, **3** and **4** co-eluted at 14.5 min, while **2** eluted at 41.1 min. In order to separate **3** and **4**, a capillary Thermo Hypercarb column (150 $\times$ 0.5 mm, 5 μ m, Thermo Fisher Scientific, Inc. Waltham, MA) was eluted with 0.05% acetic acid, pH 4.0 (A) and 100% acetonitrile (B) at the same gradient. The mass spectrometer was operated in the positive ion mode, with nitrogen used as a sheath gas (5 L/min). Electrospray ionization was achieved at a spray voltage of 4.0 kV and the capillary temperature of 270 °C. CID was achieved with Ar as a collision gas (1 mTorr) and a collision energy of 35 V. The mass spectrometer parameters were optimized for maximum response during infusion of standard solutions. Both exocyclic DEB-dA lesions were quantified by isotope dilution with the corresponding $^{15}\text{N}_4$ -labeled internal standards. Quantitative analyses were performed in the selected reaction monitoring (SRM) mode using HPLC-ESI⁺-MS/MS peak areas

corresponding to the neutral loss of deoxyribose from protonated molecules of the adducts (m/z 338.1 $[M + H]^+ \rightarrow 222.0 [M + 2H-dR]^+$ and m/z 342.1 $[M + H]^+ \rightarrow 226.0 [M + 2H-dR]^+$ for analytes and their internal standards, respectively).

Results

Synthesis and initial characterization of exocyclic DEB-dA adducts

Three isomers of exocyclic DEB-dA lesions were initially prepared. One of them (compound **2** in Scheme 1) was isolated as a side product during the synthesis of compound **1**, which was accomplished by coupling 6-chloropurine deoxyriboside with 1-amino-2-hydroxy-3,4-epoxybutane in the presence of organic base (Scheme 1) (30). Two additional DEB-dA exocycles (compounds **3** and **4**) were obtained as major products of spontaneous cyclization of **1** in an aqueous solution (Scheme 1) (30). All three exocyclic DEB-dA adducts **2**, **3** and **4** had the same molecular weight (337.2 Da) as determined by ESI⁺ MS (m/z 338, $[M+H]^+$), and their molecular formula from Q-TOF MS analysis was consistent with the addition of one molecule of DEB to deoxyadenosine (C₁₄H₁₉N₅O₅, calculated m/z 338.1459, observed m/z 338.1446).

Unlike compound **1**, which has a half life of ~ 100 min under physiological conditions (30), compounds **2**, **3** and **4** were relatively stable in an aqueous solution at pH 7.2 (with the exception of the slow interconversion of **3** and **4**, see below). Moreover, no structural changes were observed following heating for 1 hour at 85 °C (not shown). Acid hydrolysis (0.1 N HCl, 30 min at 85 °C) of nucleosides **2**, **3** and **4** cleaved the deoxyribose, while the alkylated nucleobases retained the DEB moiety, indicating that both alkylation events took place within the adenine portion of the molecule.

Three stereoisomers of **2** (**2a**, **2b**, and **2c**) were synthesized (Chart 1). Compounds **2a** and **2b** originated from *R,R,S,S* 1-amino-2-hydroxy-3,4-epoxybutane (**5a** + **5c**) and were resolved by reversed phase HPLC. **2c** was prepared from *meso* 1-amino-2-hydroxy-3,4-epoxybutane (**5b** + **5d**). The absolute configurations of compounds **2a**, **2b**, and **2c** were subsequently determined by an independent synthesis described below. The individual diastereomers of compounds **3** and **4** could not be resolved by conventional HPLC because of their polar character, which led to poor retention of these nucleosides on reversed phase HPLC columns. As described in a later section, stereospecific synthesis was subsequently used to prepare individual stereoisomers of compounds **3** and **4**.

To identify the substitution sites within the adenine heterocycle, electronic spectra of compounds **2**, **3** and **4** under different pH conditions were examined. UV absorbance spectra of DEB-dA adducts differed from that of compound **1** (Table 1 and Figure 1). While the UV spectra of compounds **2** had an absorbance maximum at neutrality of 274 nm (Figure 1B, Table 1), compounds **3** and **4** had UV absorption spectra that were nearly identical to each other and were characterized by a maximum at 264 nm (Figures 1C,D and Table 1). Under low pH conditions, the UV absorption maximum of compound **2** underwent a 6 nm hypsochromic shift, probably a result of protonation of the N-1 position of adenine (Table 1, Figure 1B). This is similar to pH dependence of the UV spectra reported for known *N*⁶-substituted deoxyadenosines (41). No such shift was observed for compounds **3** and **4**. Instead, the UV spectra of compounds **3** and **4** were transformed at a high pH, with the development of a broad shoulder between 280 and 320 nm (Figures 1C and 1D). This UV absorption behavior is characteristic for *I,N*⁶-substituted deoxyadenosines (41-44). Taken together, the UV spectroscopy data were consistent with *N*⁶ substitution of adenine in compound **2** and *I,N*⁶-substitution in compounds **3** and **4**.

Further insight into the structures of novel exocyclic DEB-dA lesions was obtained from tandem mass spectrometry experiments. The MS/MS fragmentation patterns of compounds **2**, **3** and **4** under ESI⁺-MS/MS conditions were similarly predominated by the neutral loss of deoxyribose (m/z 338.3 $\rightarrow$ 222.2 [M+2H-dR]⁺), not allowing any insight into the structures of modified bases (results not shown). However, characteristic MS³ fragmentation patterns were observed when the MS/MS product ions at m/z 222.2 were isolated and subjected to further fragmentation in an ion trap mass spectrometer (Figure 1, right panel). Compound **2** exhibited a major MS³ secondary product ion at m/z 185.9 [M+2H-dR-2H₂O]⁺ (Figure 1B). In contrast, MS³ fragmentation of compound **3** was predominated by the fragment ions at m/z 148.0 [Ade-CH₂+H]⁺ (Figure 1C), while MS³ spectrum of compound **4** was characterized by intense product ions at m/z 177.5 [Ade-CH-CH₂OH+H]⁺ (Figure 1D). Our observation of different MS³ fragmentation patterns for the three isomers of DEB-dA adducts is suggestive of significant structural differences between DEB-derived deoxyadenosine exocycles **2**, **3**, and **4**.

Periodate oxidation experiments to establish the structure of DEB-derived butanediol linker—The structure of the DEB-derived side chain in compounds **2**, **3**, and **4** was explored by periodate oxidation. To simplify the experiment, periodate oxidation was conducted with free bases of **2a**, **2b**, **2c**, **3** and **4** obtained by acid hydrolysis of the corresponding nucleosides (Chart 2). These experiments (Supporting Information, S-2) revealed the presence of a vicinal diol functionality in compounds **2a**, **2b**, and **2c**, consistent with the 1,4-butanediyl-2,3-diol structure of DEB-derived exocycle (Chart 2). In contrast, the lack of periodate reactivity toward compounds **3** and **4** indicates that they do not contain a 1,2-diol functionality (Supporting Information S-2). As described below, these results were subsequently confirmed by independent synthesis of **2**, **3**, and **4**.

Structural characterization of compounds **2** by NMR spectroscopy

Further details of the molecular structure of compounds **2**, **3**, and **4** were obtained from one- and two-dimensional NMR spectroscopy experiments. To simplify NMR signal assignment, the deoxyribose group of each nucleoside was cleaved in the presence of acid. NMR signal interpretation for the resulting nucleobase adducts (Chart 2) was facilitated by comparison with known ¹H NMR spectra of monoalkylated adenines (45-48) and 1,*N*⁶-exocyclic dA adducts of BCNU, vinyl chloride, and α,β -unsaturated aldehydes (10,42,49).

The aromatic region of the ¹H NMR spectra recorded for the compounds **2a-base**, **2b-base**, and **2c-base** was characterized by signals at 8.15 ppm (H-2 of Ade) and 8.05 ppm (H-8 of Ade). The signal of *N*⁹-H was observed at 12.88–12.89 ppm (Supporting Information S-6A, S-8 and S-9). These chemical shifts are comparable to those reported for other *N*⁶-alkyladenines (47, 50). However, unlike singly substituted *N*⁶-dA derivatives, which exhibit one- proton signal at ~ 8 ppm corresponding to the exocyclic amino group, spectra of compounds **2a-base**, **2b-base**, and **2c-base** lacked the *N*⁶-H proton signal, consistent with *bis*-alkylation of the *N*⁶ position of adenine. ¹³C chemical shifts of the aromatic part of the molecule were similar to those reported for other *N*⁶-alkyladenines (45,51). NMR spectra of compounds **2a-base** and **2b-base** were identical, consistent with their enantiomeric relationship. The presence of the pyrrolidine-2,3-diol group was supported by HSQC spectra that exhibited two methylene and two methine protons within the side chain, the TOCSY spectra that revealed strong correlations between CH₂ ^{α} and CH ^{β} protons, CH ^{β} and CH ^{γ} protons, and CH₂ ^{δ} and CH ^{γ} protons, ¹H NOESY experiments (Supporting Information S-6), and by comparison of the NMR spectra of compounds **2** with those of other pyrrolidine derivatives (52). No detectable correlations between the purine heterocycle and the pyrrolidine moiety of the molecule were detected in the gHMBC experiments (Supporting Information S-7), as is often the case for *N*⁶-substituted adenines (20,31,53). Based on NMR, MS, and periodate oxidation experiments, compounds

2a and **2b** were identified as the enantiomers of N^6,N^6 -(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine (Chart 1). Similar NMR results, with a few small differences in chemical shifts, were noted for compound **2c-base** (Supporting Information S-9). Based on the NMR, UV, and mass spectra, as well as periodate oxidation results (Supporting Information S-2), compound **2c-base** was identified as *meso* N^6,N^6 -(2,3-dihydroxybutan-1,4-diyl)-adenine (Chart 2).

Final structural assignments of compounds **2a**, **2b**, and **2c**, including their absolute configurations, were made by comparing their NMR, UV, optical rotation, and mass spectra to those of authentic *R,R*, *S,S* and *meso* N^6,N^6 -DHB-dA prepared independently. This stereospecific synthesis was accomplished by coupling 2'-deoxyinosine with optically pure 3*S*,4*S*, 3*R*,4*R* and *meso* pyrrolidine-3,4-diols. For example, protected 3*R*,4*R* pyrrolidine-2,3-diol **8** was synthesized from *D*-tartaric acid **6** as described previously (Scheme 2) (37,38). Following debenzoylation of **8**, the resulting 3*R*,4*R* pyrrolidine-3,4-diol **9** was coupled to 2'-deoxyinosine in the presence of DMSO, DIPEA and PyBOP (39) to give optically pure compound **2a** in 72% yield. The same synthetic route starting with *L*-tartaric acid and *meso*-tartaric acid was used to obtain optically pure compounds **2b** and **2c**, respectively. We found that the HPLC retention times, UV, NMR, and mass spectra of the independently prepared *R,R*, *S,S*, and *meso* N^6,N^6 -DHB-dA were identical to those of compounds **2a**, **2b**, and **2c** derived from N^6 -HEB-dA (Scheme 1), confirming their chemical structures as *S,S*, *R,R* and *meso* N^6,N^6 -(2,3-dihydroxybutan-1,4-diyl)-2'-deoxyadenosine, respectively (Chart 1).

As noted above, NMR spectra of compounds **2-base** recorded at an ambient temperature (25 °C) reveal separate signals for the two methylene protons (CH_2^α and CH_2^δ) and for the two methine protons of the pyrrolidine-2,3-diol moiety (CH^β and CH^γ). Similarly, ^{13}C NMR signals of carbons β and γ , as well as those of carbons α and δ , have slightly different chemical shifts (Supporting Information S-6B). This is in contrast with fully symmetrical ^1H and ^{13}C spectra of synthetic pyrrolidine-3,4-diols prior to their coupling with the purine heterocycle (Figures S-4 and S-5 in Supporting Information). This discrepancy can be explained by a hindered rotation about the C6-N6 bond in compounds **2**, resulting in a distinct stereoelectronic environment for carbons and hydrogens located on the opposite sides of the pyrrolidine ring (e.g. CH_2^α and CH^β versus CH^γ and CH_2^δ). This hypothesis is fully supported by density functional calculations that reveal that the lone electron pair of the pyrrolidine nitrogen is shared with the π -electron system of the purine ring, resulting in a partial double bond character for the C6-N6 bond. Conformational analyses (Supporting Information S-10-S-12) predict that the barrier of rotation about the C6-N6 bond is between 14.5 and 17.5 kcal/mol. As a result, at room temperature, one side of the pyrrolidine ring (CH_2^α and CH^β) experiences a greater ring current and a more pronounced deshielding than does the other side (CH^γ and CH_2^δ), leading to a downfield shift in the ^1H and ^{13}C NMR spectra.

To confirm the results of this computational study experimentally, temperature-dependent ^1H NMR spectra of compounds **2a** and **2b** were recorded. As the temperature was increased from 25 °C to 50, 65, and 85 °C, proton signals corresponding to CH^β and CH^γ merged, yielding a single two proton signal at 4.04 ppm (Supporting information S-13). Similarly, the signals corresponding to CH_2^α and CH_2^δ coalesced at an increased temperature, although a higher temperature (~ 85 °C) was required because of a greater separation of their chemical shifts (4.21, 4.00 and 3.69, 3.62 ppm, respectively). Taken together, our results suggest that the bond rotation along the C6-N6 bond of compounds **2** under physiological temperature is hindered, resulting in an asymmetric structure.

Structural characterization of compound 3: 1,*N*⁶-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (compound 3)

Since compound **3** was obtained by spontaneous cyclization of compound **1** (in Scheme 1), adenine substitution pattern of the resulting exocycle must include the *N*⁶ position of adenine. As discussed above, the UV spectral data for **3** are indicative of the *1,N*⁶ dialkylation (Figure 1C). Further proof of the *1,N*⁶-substitution of adenine in compound **3** is obtained from gHMBC and 2-D NOESY spectra (Figures 2B,D and Supporting Information S-14-S16, S-21). In particular, gHMBC signals are found between the C-6 of adenine and the CH₂^α protons of the side chain (Figure 2B), as well as a correlation is observed between the carbon γ of the side chain and the H-2 proton of the adenine heterocycle (Figure 2D). Furthermore, NOESY correlations are observed between the H-2 proton of the adenine nucleobase and CH'^γ proton of the side chain of compounds **3**, **3a** and **3b**.

The detailed structures of compounds **3a** and **3b** were established by considering the results of two-dimensional NMR experiments. A phase-sensitive HSQC (¹H-¹³C) experiment (Figure 2C) was instrumental for distinguishing between methylene and methine protons within the DEB-derived exocycle. The diastereotopic methylene protons of the CH₂^δ group were observed as two multiplets at 3.59 and 3.39 ppm (Figure 2A). According to the HMQC & HSQC data, these two protons are attached to the same carbon atom (61.9 ppm, Supporting Information S-12). These two protons couple with each other in the COSY and NOESY spectra, confirming their geminal nature. Furthermore, the CH₂^δ group is connected to a hydroxyl based on the results of COSY experiments (Supporting Information S-14). Taken together with the results of periodate oxidation (Supporting Information S-2), these data establish the structure of **3** as *1,N*⁶-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (Chart 1).

This structural assignment is supported by comparing the NMR and UV data of compound **3** with those published for other *1,N*⁶-dA exocyclic compounds, e.g. *1,N*⁶-(propano)-2'-deoxyadenosine (53) and *1,N*⁶-(2-hydroxypropano)-2'-deoxyadenosine (43). Density functional calculations predict that the distance between H-2 and CH'^γ protons in *1,N*⁶-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine is 2.21 Å (Figure 3A below), consistent with the NOESY results discussed above.

Despite single substitution of the exocyclic amino group in compound **3**, no ¹H NMR signal corresponding to the exocyclic NH proton is observed (Figure 2A). Other N1-alkyladenines are known to be positively charged in aqueous solutions at a neutral pH (the pK_a of 1-methyladenine is 8.25)(45), with the charge localized mainly at the N1 position. HPLC behavior of compounds **3** and **4**, e.g. their poor retention on reversed phase HPLC columns in the absence of ion pairing reagents, but strong retention on cation exchange columns at pH 7, suggests that they are charged species under aqueous conditions, containing a proton at the *N*⁶ and a double bond between the C6 and the N1 (Scheme 3). Further support for the presence of a positive charge on the N-1 under aqueous conditions is obtained from the downfield shifts of the NMR signals of H-2, C-2, C-6 compared to the corresponding signals in dA. The proton NMR signal of H-2 in **3** is shifted downfield by 0.6 ppm when the spectrum is recorded in D₂O relative to that in dry DMSO (Figure S-25 in Supporting Information). This shift is greater than can be accounted for by solvent effect and is consistent with the presence of a positive charge when compound **3a** is dissolved in water. This NMR behavior analogous to that of structurally similar *1,N*⁶-dA exocyclic adducts containing a positive charge on the N-1 (43). We hypothesize that NMR sample drying under high vacuum conditions leads to deprotonation of the *N*⁶-H (and the removal of acetic acid) and the formation of the N6-C6 double bond (Scheme 3), explaining the absence of the *N*⁶-H proton signal in the ¹H NMR spectrum of compound **3a** (Figure 2A).

Structural characterization of compound 4: 1,*N*⁶-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (compound 4)

UV spectroscopy results for compound **4** discussed above (Figure 1 and Table 1) are consistent with the 1,*N*⁶-ring substitution pattern, while periodate oxidation experiments establish the absence of a vicinal diol functionality (Supporting Information S-2). Furthermore, UV absorbance spectra (Figure 1) and the downfield regions of the ¹H NMR spectra of compound **4** (Supporting Information S-17, S-18) are identical to those of compound **3**, suggesting that they have the same adenine ring substitution patterns. However, our observation of distinct MS³ spectra and significant differences within the upfield regions of the ¹H NMR spectra of compounds **3** and **4** (see Figures 1C and D (right panel), Supporting Information S-17, S-18) suggests that they have different side chain structures.

Two-dimensional NMR experiments were used to establish the exact connectivity between the adenine heterocycle and the DEB-derived side chain in compound **4**. In particular, NOESY correlations between the H-2 adenine proton and both CH₂^γ protons within the propano exocycle were observed (Supporting Information S-17, S-18). Furthermore, HMBC correlations were detected between the two CH₂^γ protons (3.95 and 3.80 ppm) and the C-2 carbon of adenine (148.6 ppm) of **4a**, strongly suggesting that a terminal methylene group of DEB is connected to the N-1 position of adenine (Supporting Information S-17). On the other side, the N⁶ position of adenine is bound to an internal carbon of DEB as indicated by the presence of the HMBC correlation between the CH^α proton (3.48 ppm) and the C-6 carbon atom of nucleobase (142.3 ppm) (Supporting Information S-17 and S-18). Taken together, these results are consistent with the structure of 1,*N*⁶-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine for compound **4**. According to our density functional calculations, the distances between the H-2 of adenine and the two γ methylene protons in 1,*N*⁶-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine are 2.23 and 3.06 Å, respectively (Figure 3B below), consistent with the NOESY results for compound **4** (Supporting Information S-17, S-18).

Stereospecific synthesis of compounds 3a, 3b, 4a, and 4b and the assignment of their absolute configuration

In order to establish the absolute configuration of compounds **3a**, **3b**, **4a**, and **4b**, stereospecific synthesis of each isomer was required. In our synthetic scheme, racemic 1-aminobut-3-ene-2-ol **11** was derived from the addition of trimethylsilyl cyanide to acrolein to generate a protected cyanohydrin **10**, which was subjected to reduction with lithium aluminum hydride (Scheme 4) (30,31). The racemic mixture of 1-amino-3-butene-2-ols **11** was separated by diastereomeric resolution following derivatization with sodium [(1*R*)-(endo, anti)]-(+)-3-bromocamphor-8-sulfonic acid ammonium salt to give crystals of **12** (Scheme 4)(32,33). The absolute configuration of the derivatized 1-amino-3-butene-2-ol **12** (*S*), was established by X-ray crystallography (Supporting Information S-20). Following crystal isolation, (*S*) 1-aminobut-3-ene-2-ol **13** was regenerated by alkaline hydrolysis. Fmoc protected 1-aminobut-3-ene-2-ol **14** was subjected to epoxidation in the presence of mCPBA to give diastereomeric 1-amino-3,4-epoxybut-2-ols **5a** and **5b** (30), which were resolved by preparative HPLC (Scheme 4). The other two isomers (**5c** and **5d** in Chart 1) were obtained analogously using (*R*) 1-aminobut-3-ene-2-ol isolated from the mother liquor following crystallization of **12**, followed by alkaline hydrolysis.

Two sets of coupling conditions were tested for the coupling of Fmoc-protected 1-amino-3,4-epoxybut-2-ols with the purine heterocycle. Coupling of **5a** with 6-chloropurine-2'-deoxyriboside for 3 days in the presence of DIPEA gave compound **1a** with 71% maximum yield (Scheme 4). An improved yield of **1a** (95%) was achieved by coupling of **5a** with 2'-deoxyinosine in the presence of PyBOP for 5 days (39). Optically pure compounds **3a** and

4a were obtained by spontaneous cyclization of **1a** in water overnight at 25 °C, followed by reversed phase HPLC purification (Scheme 4). Analogous reactions of **5b** produced monoepoxide **1b**, which cyclized to compounds **3b** and **4b** (7:3 molar ratio by HPLC). Further experiments indicated that compounds **3a** and **3b** can be generated selectively in a 98% yield when the cyclization time is decreased to 3 hours. Interestingly, the stereochemistry of the oxirane ring in **1a** and **1b** did not affect their cyclization kinetics ($t_{1/2}$ at 37 °C in water was ~ 58 min for both isomers - see Supporting Information S-19).

The absolute configurations of stereogenic centers within the propano group of compound **3a** (β and γ in Chart 1) were assigned as follows. The configuration at the β position of **3a** should be *R* because it is obtained by cyclization of **1a**, which has the βR , γR stereochemistry (Scheme 4), and the β stereocenter is unchanged in this reaction. In contrast, the optical configuration of the γ carbon is inverted as a result of S_N2 type nucleophilic substitution at this position, resulting in the *S* stereochemistry (Scheme 4). This assignment is experimentally confirmed by the lack of spacial correlations between the β and the γ protons in the NOESY NMR spectrum of **3a** (Supporting Information S-15). Similarly, the chiral centers within the propane moiety of **3b** were assigned as βR , γR , because it was obtained by intramolecular nucleophilic substitution of βR , γS -1-amino-2-hydroxy-3,4-epoxybutane **1b**, which was experimentally confirmed by the presence of NOESY NMR signals between the β and γ protons of **3b** (Supporting Information S-16). Density functional calculations predict that the distance between β and γ protons in βR , γR -1, N^6 -(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine is between 2.3–2.4 Å, depending on the conformation of the γ -hydroxymethyl group (Figure 3A), corroborating the observed NOESY correlations and supporting the stereochemical assignment of **3b**.

The absolute stereochemistry of compound **4a** was assigned as αS , βR based on the mechanism of its formation *via* isomerization of **3a** (see below) and the absence of the NOE correlations between the β and α protons (Supporting Information S-17). Similarly, compound **4b** was assigned the αR , βR configuration, supported by the observation of NOE correlations between the β and α protons of **4b** and density functional calculations (Figure 3B and Supporting Information S-18).

Compounds **1c** and **1d** and their cyclization products **3c**, **4c**, **3d**, and **4d** (Chart 1) were generated analogously starting with **5c** and **5d**, respectively.

Solvent dependent regioselectivity for cyclization of compound 1

As discussed above, compound **1** spontaneously cyclizes to form the corresponding 1, N^6 exocyclic compound **3** when allowed to incubate in water under physiological pH (Scheme 1). In contrast, the N^6 , N^6 exocycle **2** is not observed when **1** is allowed to cyclize in an aqueous solution. Instead, **2** becomes a significant side product from the coupling reaction of 6-chloropurine-2'-deoxyriboside with 1-amino-3,4-epoxybut-2-ol when the coupling time is extended to > 3 days (Scheme 1, Supporting Information S-3). The same product **2** is generated when purified **1** is incubated under our standard coupling conditions (DMSO in the presence of DIPEA) (Scheme 1).

Taken together, these results indicate that the regioselectivity of cyclization of compound **1** is determined by solvent identity. Under aqueous conditions, **1** spontaneously cyclizes to **3**, while **2** is preferentially formed in an aprotic solvent (DMSO) in the presence of organic base (Scheme 1). These results can be explained by the altered nucleophilicity of the N^6 and the *NI* of **1** under these two sets of conditions, likely a result of N^6H deprotonation in an aprotic solvent in the presence of *N,N*-diisopropylethyl amine.

Forced Dimroth rearrangement of compound **3** to compound **4**

While the formation of compound **3** from compound **1** can be explained by intramolecular nucleophilic substitution (Scheme 1), no such mechanism can be proposed for compound **4**. Kinetic analyses indicate that **3** originates directly from **1**, but there is a delay in the formation of **4**, which requires extended incubation times (Supporting Information S-22). We hypothesized that compound **4** is formed from **3** by a base-catalyzed Dimroth rearrangement (Scheme 5). To test this hypothesis, **3a** was subjected to forced Dimroth rearrangement in aqueous NaOH (54). Capillary HPLC analysis of the reaction mixture revealed the presence of compounds **3a** and **4a** in a 3:7 molar ratio (Figure 4C). Interestingly, same product ratio was observed when purified **4a** was subjected to forced Dimroth rearrangement (not shown).

An additional nucleoside product **15** was observed while analyzing the reaction mixture from Dimroth rearrangement by capillary HPLC. It was tentatively assigned the structure of 2-(5-amino-1-(2'-deoxy-pentofuranosyl)-imidazol-4-yl)-4-(hydroxymethyl)-tetrahydropyrimidin-5-ol (compound **15** in Figure 4C and Supporting information S-24) based on its UV absorption spectra ($\lambda_{\text{max}} = 284 \text{ nm}$) and MS/MS fragmentation pattern. We hypothesized that this compound produced by a hydroxyl ion attack on compounds **3** or **4**, followed by a loss of CO as proposed by Sugiyama et al. for structurally related compounds (55).

To determine whether Dimroth rearrangement of compounds **3** and **4** can take place under mild conditions, purified compounds **3a** and **4a** were individually dissolved in water and incubated at room temperature or at 37 °C for up to 5 days. The rearrangement products were detected by HPLC-ESI⁺-MS/MS (Supporting Information S-23). We observed a slow conversion of **3a** to **4a** at room temperature (12 % in 5 days) and a faster rearrangement at 37 °C (66 % in 5 days). In contrast, the formation of **3a** from **4a** was inefficient under both conditions (only 20 % at 37 °C in 5 days). Irrespective of the temperature, the same molar ratio (70% of **4a** and 30 % of **3a**) was observed when either **3a** or **4a** was allowed to equilibrate in water for a sufficient time (16 days). Kinetic analyses of this conversion (Supporting Information S-23) reveal that the half lives for the conversion of **3a** → **4a** and **4a** → **3a** are 71.5 h and 365 h, respectively. Taken together, these results indicate that **4a** and **3a** can be interconverted under physiological pH, with the equilibrium shifted towards **4a** as a more thermodynamically stable product. Density functional calculations support this finding as compound **4a** is 1.9 kcal/mol lower in energy than **3a**. We hypothesize that the additional stability of **4a** is derived mainly from formation of an intramolecular hydrogen bond between the N6-H and the hydroxymethyl oxygen of the exocycle (Figure 3C).

Detection of exocyclic DEB-dA adducts in DEB-treated DNA and in liver DNA of BD exposed mice

To establish whether exocyclic DEB-dA adducts **2**, **3** and **4** are biologically relevant, aliquots of double stranded DNA (calf thymus DNA) were separately treated with *S,S*, *R,R* or *meso* DEB (Scheme 6). All three isomers of DEB were employed in order to investigate potential effects of diepoxide chirality on exocyclic DEB-dA adduct formation. The resulting alkylated DNA was enzymatically digested to deoxynucleosides, spiked with ¹⁵N₄-labeled compounds **3** and **4** (internal standards for mass spectrometry), and purified by solid phase extraction. HPLC-ESI⁺-MS/MS analysis of samples treated with *R,R* DEB revealed two major peaks eluting at 12.4 and 17.7 min (Figure 5A), which were identified as compounds **3a** and **4a**, respectively, based on their MS³ fragmentation patterns and HPLC retention times. Similar results were obtained for *S,S* DEB (Figure 5B), since compounds **3c** and **4c** originating from *S,S* DEB have the same HPLC retention times as **3a** and **4a**, respectively. Samples treated with *meso* DEB revealed HPLC-ESI-MS/MS signals at 19.2 and 21.3 min, corresponding to compounds **4b/4d** and **3b/3d**, respectively. In all the cases, the amounts of compound **4** were

greater than compound **3**. In contrast, compounds **2** were not found in DNA hydrolysates, although small amounts were detected in a separate experiment using > 200 molar excess of DEB (results not shown).

The amounts of compounds **3** and **4** present in DNA hydrolysates were calculated from HPLC-ESI-MS/MS peak areas corresponding to the analytes and the corresponding internal standards. As shown in Figure 5D, concentrations of exocyclic $1,N^6$ -DEB-dA adducts increased linearly as the concentration of DEB was gradually raised from 50 to 1000 μ M. Similar numbers of exocyclic DEB-dA adducts were observed in DNA treated with *S,S*, *R,R* or *meso* DEB, suggesting that the DEB isomers are equally capable of inducing exocyclic adenine lesions in DNA. This is in contrast with our earlier results for DNA cross-linking by DEB isomers, which revealed that the *S,S* isomer formed the highest numbers of interstrand guanine-guanine lesions, while *meso* DEB induced equal numbers of intrastrand and interstrand *bis*-N7G-BD lesions (21).

Adducts **3** and **4** were also present in genomic DNA isolated from liver of laboratory mice exposed to 1,3-butadiene by inhalation (Figure 5E). Compounds **4a/4c** (61%) were the most abundant, followed by **4b/4d** (27%) and **3a/3c** (12%) (the individual isomers of **4a/4c** and **3a/3c** are not resolved under our HPLC conditions). The presence of stereoisomers of **3** and **4** *in vivo* is consistent with non-stereoselective metabolic activation of 1,3-butadiene to *S,S*, *R,R*, and *meso* DEB (Scheme 6) (14). As previously observed for guanine-guanine cross-links of DEB (40), exocyclic dA adducts originating from *S,S*+*R,R* DEB (**3a**, **4a**, **3c**, **4c**) are more abundant than the corresponding lesions of *meso* DEB (**3b**, **4b**, **3c**, **4c**, see Scheme 6 and Figure 5E). This may be explained by greater amounts of *S,S* and *R,R* diepoxides produced upon metabolic activation of BD as compared with *meso* DEB. Studies using cDNA-expressed human P450 monooxygenases have shown that individual P450s can generate *meso* and racemic DEB in different molar ratios (56). In particular, P450 2A6 and 2E1 favor *meso* over racemic DEB, whereas 2C9 forms equal levels of each (56). Alternatively, mice may detoxify *meso* DEB at a faster rate than racemic *bis*-N7G-BD. For example, epoxide hydrolase (EH), an enzyme that detoxifies DEB by hydrolyzing the epoxide ring to a diol, has been reported to hydrolyze *meso* DEB at a faster rate than *S,S* and *R,R* diepoxides (56), potentially leading to smaller amounts of *meso* DEB available for reactions with DNA.

Taken together, our results indicate that the major exocyclic DEB-dA adducts produced following *in vitro* or *in vivo* exposure of DNA to DEB have the structures of $1,N^6$ -(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (compound **4**) and $1,N^6$ -(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (compound **3**). Although the amounts of adducts **3** and **4** in liver DNA following exposure to 1,3-butadiene are significantly lower than the numbers of DEB-induced DNA-DNA cross-links, 1,4-*bis*-(guan-7-yl)-2,3-butanediol (*bis*-N7G-BD) and 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD) (the molar ratio of *bis*-N7G-BD: N7G-N1A-BD: adducts **3** and **4** are 1:0.08:0.03), exocyclic DEB-dA lesions are hydrolytically stable and may persist *in vivo*. Indeed, our recent studies indicate that **3** and **4** are persistent in mouse liver at least 2 weeks following exposure (Goggin and Tretyakova, manuscript in preparation). Compounds **3** and **4** are not substrates for base excision repair or nucleotide excision repair, leading to their potential accumulation in target tissues (Goggin and Tretyakova, manuscript in preparation). Based on these observations, we hypothesize that compounds **3** and **4** play an important role in mutagenicity and carcinogenicity of 1,3-butadiene.

Concluding remarks

Our results presented above are the first report for the formation of potentially promutagenic exocyclic DEB-dA lesions, which have the structures of N^6,N^6 -(2,3-dihydroxybutan-1,4-

diyl)-2'-deoxyadenosine (compound **2** in Chart 1), *1,N*⁶-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (compound **4**), and *1,N*⁶-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (compound **3**). The structural identities and optical configurations of the novel nucleosides were confirmed by an independent stereospecific synthesis. We hypothesize that in DNA under physiological conditions, DEB alkylates the N-1 position of adenine in DNA to form N1-(2-hydroxy-3,4-epoxybut-1-yl)-adenine adducts, which undergo spontaneous intramolecular nucleophilic substitution to yield compound **4** (Scheme 7A). The minor regioisomer **3** is formed either by alkylation of the *N*⁶ of adenine bases by DEB, followed by cyclization (Scheme 7B), or by Dimroth-like rearrangement of **4** (Scheme 5). Compounds **3** and **4** are interconverted under physiological conditions by a reversible reaction favoring **4** as a more stable thermodynamic product. While Dimroth rearrangement is expected to be slow at physiological pH, an alternative mechanism based on low energy unimolecular pericyclic reactions (57) may explain the formation of **4** from **3** (Scheme 8).

Compounds **4a/4c** were the most abundant exocyclic DEB-dA adducts observed in DEB-treated DNA, and also in DNA extracted from liver tissues of laboratory mice exposed to 1,3-butadiene by inhalation. Levels of compounds **3** and **4** in DNA increased with DEB concentration, and little difference in reactivity was observed for the three isomers of DEB (Figure 5D).

While the biological significance of the novel DEB-dA lesions discovered in this work remains to be established, they may be responsible for the ability of 1,3-butadiene and DEB to induce a large number of A → T mutations (site specific mutagenesis experiments are in progress). Since Watson-Crick base-pairing of compounds **3** and **4** with dT is blocked by the (1-hydroxymethyl-2-hydroxy-1,3-propano) exocycle, the modified nucleoside is likely to adopt the *syn* conformation about the glycosidic bond as previously observed for *1,N*⁶-εdA and *N1*-HB-dI adducts (4,5,10,58), preventing accurate replication. We hypothesize that the modified dA forms a Hoogsteen base pair with the incoming protonated dATP, leading to A → T transversions. The synthetic methodologies established in the present work have been recently used to generate DNA oligodeoxynucleotides containing site- and stereospecific adducts **2**, **3**, and **4** (Seneviratne and Tretyakova, manuscript in preparation). Our ongoing studies are employing solution NMR and site specific mutagenesis to establish the effects of the novel DEB-dA lesions on DNA structure and DNA polymerase fidelity.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Kris Murphy for optimizing the yields of several key synthetic steps, Brock Matter (University of Minnesota Cancer Center) for his assistance with the HPLC and mass spectrometry experiments, Victor G. Young, Jr. (X-Ray Crystallographic Laboratory, Department of Chemistry) for conducting crystallography experiments, and Bob Carlson (University of Minnesota Cancer Center) for preparing figures for this manuscript. NMR instrumentation was provided with funds from the NSF (BIR-961477), the University of Minnesota Medical School, and the Minnesota Medical Foundation. This research is supported by grants from the NCI (R01 CA095039) and the Health Effects Institute (Agreement 05-12). A.M. is grateful for support through a Department of Energy NDSEG fellowship. Computational resources were provided by the Minnesota Supercomputing Institute.

References

1. Blair IA. DNA adducts with lipid peroxidation products. *J Biol Chem* 2008;283:15545–15549. [PubMed: 18285329]

2. Yang IY, Hashimoto K, de Wind N, Blair IA, Moriya M. Two distinct translesion synthesis pathways across a lipid peroxidation-derived DNA adduct in mammalian cells. *J Biol Chem* 2009;284:191–198. [PubMed: 18981176]
3. Medeiros MH. Exocyclic DNA adducts as biomarkers of lipid oxidation and predictors of disease. Challenges in developing sensitive and specific methods for clinical studies. *Chem. Res. Toxicol* 2009;22:419–425.
4. Nair DT, Johnson RE, Prakash L, Prakash S, Aggarwal AK. Hoogsteen base pair formation promotes synthesis opposite the 1,*N*⁶-ethenodeoxyadenosine lesion by human DNA polymerase ι . *Nat. Struct. Mol. Biol* 2006;13:619–625. [PubMed: 16819516]
5. Basu AK, McNulty JM, McGregor WG. Solution conformation and mutagenic specificity of 1,*N*⁶-ethenoadenine. *IARC Sci. Publ* 1999;325–333. [PubMed: 10626232]
6. Fink SP, Reddy GR, Marnett LJ. Mutagenicity in *Escherichia coli* of the major DNA adduct derived from the endogenous mutagen malondialdehyde. *Proc. Natl. Acad. Sci. U. S. A* 1997;94:8652–8657. [PubMed: 9238032]
7. Marnett LJ, Burcham PC. Endogenous DNA adducts: potential and paradox. *Chem. Res. Toxicol* 1993;6:771–785. [PubMed: 8117915]
8. VanderVeen LA, Hashim MF, Nechev LV, Harris TM, Harris CM, Marnett LJ. Evaluation of the mutagenic potential of the principal DNA adduct of acrolein. *Journal of Biological Chemistry* 2001;276:9066–9070. [PubMed: 11106660]
9. Basu AK, Wood ML, Niedernhofer LJ, Ramos LA, Essigmann JM. Mutagenic and genotoxic effects of three vinyl chloride-induced DNA lesions: 1,*N*⁶-ethenoadenine, 3,*N*⁴-ethenocytosine, and 4-amino-5-(imidazol-2-yl)imidazole. *Biochemistry* 1993;32:12793–12801. [PubMed: 8251500]
10. de los Santos C, Kouchakdjian M, Yarema K, Basu A, Essigmann J, Patel DJ. NMR studies of the exocyclic 1,*N*⁶-ethenodeoxyadenosine adduct (edA) opposite deoxyguanosine in a DNA duplex. ϵ -dA(syn).dG(anti) pairing at the lesion site. *Biochemistry* 1991;30:1828–1835. [PubMed: 1993197]
11. Swenberg JA, Boysen G, Georgieva N, Bird MG, Lewis RJ. Future directions in butadiene risk assessment and the role of cross-species internal dosimetry. *Chem. Biol. Interact* 2007;166:78–83. [PubMed: 17343837]
12. Morrow NL. The industrial production and use of 1,3-butadiene. *Environ. Health Perspect* 1990;86:7–8. [PubMed: 2205493]
13. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J. Natl. Cancer Inst* 1999;91:1194–1210. [PubMed: 10413421]
14. Krause RJ, Elfarrar AA. Oxidation of butadiene monoxide to meso- and ($\pm$)-diepoxybutane by cDNA-expressed human cytochrome P450s and by mouse, rat, and human liver microsomes: evidence for preferential hydration of meso-diepoxybutane in rat and human liver microsomes. *Arch. Biochem. Biophys* 1997;337:176–184. [PubMed: 9016811]
15. Thornton-Manning JR, Dahl AR, Bechtold WE, Griffith WC Jr, Henderson RF. Comparison of the disposition of butadiene epoxides in Sprague-Dawley rats and B6C3F1 mice following a single and repeated exposures to 1,3-butadiene via inhalation. *Toxicology* 1997;123:125–134. [PubMed: 9347927]
16. Sasiadek M, Norppa H, Sorsa M. 1,3-Butadiene and its epoxides induce sister-chromatid exchanges in human lymphocytes in vitro. *Mutat. Res* 1991;261:117–121. [PubMed: 1922154]
17. Cochrane JE, Skopek TR. Mutagenicity of butadiene and its epoxide metabolites: I. Mutagenic potential of 1,2-epoxybutene, 1,2,3,4-diepoxybutane and 3,4-epoxy-1,2-butanediol in cultured human lymphoblasts. *Carcinogenesis* 1994;15:713–717. [PubMed: 8149485]
18. Henderson RF, Thornton-Manning JR, Bechtold WE, Dahl AR. Metabolism of 1,3-butadiene: species differences. *Toxicology* 1996;113:17–22. [PubMed: 8901878]
19. Park S, Tretyakova N. Structural characterization of the major DNA-DNA cross-link of 1,2,3,4-diepoxybutane. *Chem. Res. Toxicol* 2004;17:129–136. [PubMed: 14966999]
20. Park S, Hodge J, Anderson C, Tretyakova NY. Guanine-adenine cross-linking by 1,2,3,4-diepoxybutane: potential basis for biological activity. *Chem. Res. Toxicol* 2004;17:1638–1651. [PubMed: 15606140]

21. Park S, Anderson C, Loeber R, Seetharaman M, Jones R, Tretyakova N. Interstrand and intrastrand DNA-DNA cross-linking by 1,2,3,4-diepoxybutane: role of stereochemistry. *J. Am. Chem. Soc* 2005;127:14355–14365. [PubMed: 16218630]
22. Verly WG, Brakier L, Feit PW. Inactivation of the T7 coliphage by the diepoxybutane stereoisomers. *Biochim. Biophys. Acta* 1971;228:400–406. [PubMed: 4925823]
23. Matagne R. Induction of chromosomal aberrations and mutations with isomeric forms of L-threitol-1,4-bismethanesulfonate in plant materials. *Mutat. Res* 1969;7:241–247. [PubMed: 5796521]
24. Kim MY, Tretyakova NY, Wogan GN. Mutagenesis of the supF gene by stereoisomers of 1,2,3,4-diepoxybutane. *Chem. Res. Toxicol* 2007;20:790–797. [PubMed: 17428069]
25. Zhang XY, Elfarra AA. Identification and characterization of a series of nucleoside adducts formed by the reaction of 2'-deoxyguanosine and 1,2,3,4-diepoxybutane under physiological conditions. *Chem. Res. Toxicol* 2003;16:1606–1615. [PubMed: 14680375]
26. Zhang XY, Elfarra AA. Characterization of the reaction products of 2'-deoxyguanosine and 1,2,3,4-diepoxybutane after acid hydrolysis: formation of novel guanine and pyrimidine adducts. *Chem. Res. Toxicol* 2004;17:521–528. [PubMed: 15089094]
27. Zhang XY, Elfarra AA. Reaction of 1,2,3,4-diepoxybutane with 2'-deoxyguanosine: initial products and their stabilities and decomposition patterns under physiological conditions. *Chem. Res. Toxicol* 2005;18:1316–1323. [PubMed: 16097805]
28. Recio L, Steen AM, Pluta LJ, Meyer KG, Saranko CJ. Mutational spectrum of 1,3-butadiene and metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane to assess mutagenic mechanisms. *Chem. Biol. Interact* 2001;135–136:325–341.
29. Cochrane JE, Skopek TR. Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the *hprt* locus in splenic T cells from exposed B6C3F1 mice. *Carcinogenesis* 1994;15:719–723. [PubMed: 8149486]
30. Antsyovich S, Quirk Dorr D, Pitts C, Tretyakova N. Site specific N⁶-(2-hydroxy-3,4-epoxybutyl)adenine oligodeoxynucleotide adducts of 1,2,3,4-diepoxybutane: synthesis and stability at physiological pH. *Chem. Res. Toxicol* 2007;20:641–649. [PubMed: 17355152]
31. Quirk Dorr D, Murphy K, Tretyakova N. Synthesis of DNA oligodeoxynucleotides containing structurally defined N⁶-(2'-hydroxy-3',4'-buten-1'-yl)-adenine adducts of 3,4-epoxy-1-butene. *Chem. Biol. Interact.* 2006 ASAP articles.
32. Ettlinger. Synthesis of the natural antithyroid factor 1-5-vinyl-2-thiooxazolidone. *J. Am. Chem. Soc* 1950;72:4792–4796. and, M. G.
33. Kjaer A, Christensen BW, Hansen SE. isothiocyanates. XXXIV. The absolute configuration of (–)-5-Vinyl-2-oxazolidinethione (goitrin) and its glucosidic progenitor (progoitrin). *Acta Chemica Scandinavica* 1959;13:144–150.
34. Giese TJ, Gregersen BA, Liu Y, Nam K, Mayan E, Moser A, Range K, Faza ON, Lopez CS, de Lera AR, Schaftenaar G, Lopez X, Lee T-S, Karypis G, York DM. *QCRNA* 1.0: A database of quantum calculations for RNA catalysis. *J. Mol. Graphics Modell* 2006;25:423–433.
35. Becke AD. Density-functional exchange-energy approximation with correct asymptotic behavior. *Phys. Rev. A* 1988;38:3098–3100. [PubMed: 9900728]
36. Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B Condens. Matter* 1988;37:785–789. [PubMed: 9944570]
37. Wong CM, Buccini J, Te Raa J. Synthesis of optically active deacetyl anisomycin. *Can. J. Chem* 1968;46:3091–3094.
38. Arakawa Y, Yoshifuji S. Synthesis of (3*S*,4*S*)-3,4-dihydroxyprolines from L-tartaric acid. *Chem. Pharm. Bull* 2007;39:2219–2224.
39. Wan ZK, Binnun E, Wilson DP, Lee J. A highly facile and efficient one-step synthesis of N⁶-adenosine and N⁶-2'-deoxyadenosine derivatives. *Org. Lett* 2005;7:5877–5880. [PubMed: 16354089]
40. Goggin M, Loeber R, Park S, Walker V, Wickliffe J, Tretyakova N. HPLC-ESI+-MS/MS analysis of N7-guanine-N7-guanine DNA cross-links in tissues of mice exposed to 1,3-butadiene. *Chem. Res. Toxicol* 2007;20:839–847. [PubMed: 17455958]
41. Singer, B.; Grunberger, D. *Molecular Biology of Mutagens and Carcinogens*. Plenum Press; New York and London: 1983.

42. Maruenda H, Chenna A, Liem L-K, Singer B. Synthesis of *1,N*⁶-ethano-2'-deoxyadenosine, a metabolic product of 1,3-bis(2-chloroethyl)nitrosourea, and its incorporation into oligomeric DNA. *J. Org. Chem* 1998;63:4385–4389.
43. Pawlowicz AJ, Munter T, Klika KD, Kronberg L. Reaction of acrolein with 2'-deoxyadenosine and 9-ethyladenine-formation of cyclic adducts. *Bioorg. Chem* 2006;34:39–48. [PubMed: 16343591]
44. Singh US, Decker-Samuelian K, Solomon JJ. Reaction of epichlorohydrin with 2'-deoxynucleosides: characterization of adducts. *Chem. Biol. Interact* 1996;99:109–128. [PubMed: 8620562]
45. Fujii T, Itaya T. Systematic tables of mono- and poly-N-methylated adenines: acid dissociation constants and UV and NMR spectral data. *Heterocycles* 1999;51:2255–2277.
46. Macon JB, Wolfenden R. 1-Methyladenosine. Dimroth rearrangement and reversible reduction. *Biochemistry* 1968;7:3453–3458. [PubMed: 5681457]
47. Tretyakova N, Sangaiah R, Yen TY, Gold A, Swenberg JA. Adenine adducts with diepoxybutane: isolation and analysis in exposed calf thymus DNA. *Chem. Res. Toxicol* 1997;10:1171–1179. [PubMed: 9348440]
48. Mikhailov SN, Rozenski J, Efimtseva EV, Busson R, Van Aerschot A, Herdewijn P. Chemical incorporation of 1-methyladenosine into oligonucleotides. *Nucleic Acids Res* 2002;30:1124–1131. [PubMed: 11861902]
49. Sanchez AM, Minko IG, Kurtz AJ, Kanuri M, Moriya M, Lloyd RS. Comparative evaluation of the bioreactivity and mutagenic spectra of acrolein-derived α -HOPdG and γ -HOPdG regioisomeric deoxyguanosine adducts. *Chem. Res. Toxicol* 2003;16:1019–1028. [PubMed: 12924930]
50. Selzer RR, Elfarra AA. Characterization of N1- and N6-adenosine adducts and N1-inosine adducts formed by the reaction of butadiene monoxide with adenosine: evidence for the N1-adenosine adducts as major initial products. *Chem. Res. Toxicol* 1996;9:875–881. [PubMed: 8828924]
51. Chang CJ, Ashworth DJ, Chern LJ, Gomes JD, Lee CG, Narayan R. ¹³C NMR studies of methyl nucleosides. *Org. Magn. Reson* 1984;12:671–675.
52. Jayaraj K, Georgieva NI, Gold A, Sangaiah R, Koc H, Klapper DG, Ball LM, Reddy AP, Swenberg JA. Synthesis and characterization of peptides containing a cyclic Val adduct of diepoxybutane, a possible biomarker of human exposure to butadiene. *Chem. Res. Toxicol* 2003;16:637–643. [PubMed: 12755593]
53. Smith RA, Williamson DS, Cerny RL, Cohen SM. Detection of 1,*N*⁶-propanodeoxyadenosine in acrolein-modified polydeoxyadenylic acid and DNA by ³²P postlabeling. *Cancer Res* 1990;50:3005–3012. [PubMed: 2334905]
54. Shallop AJ, Gaffney BL, Jones RA. Use of ¹³C as an indirect tag in ¹⁵N specifically labeled nucleosides. Syntheses of [8-¹³C-1,7,NH₂-¹⁵N₃]adenosine, -guanosine, and their deoxy analogues. *J. Org. Chem* 2003;68:8657–8661. [PubMed: 14575499]
55. Sugiyama T, Schweinberger E, Kazimierczuk Z, Ramzaeva N, Rosemeyer H, Seela F. 2-aza-2'-deoxyadenosine: synthesis, base-pairing selectivity, and stacking properties of oligonucleotides. *Chemistry* 2000;6:369–378. [PubMed: 11931118]
56. Kemper RA, Krause RJ, Elfarra AA. Metabolism of butadiene monoxide by freshly isolated hepatocytes from mice and rats: different partitioning between oxidative, hydrolytic, and conjugation pathways. *Drug Metab. Dispos* 2001;29:830–836. [PubMed: 11353751]
57. Silva LC, Alvarez R, Dominguez M, Nieto FO, de Lera AR. Complex thermal behavior of 11-cis-retinal, the ligand of the visual pigments. *J. Org. Chem* 2009;74:1007–1013. [PubMed: 19178351]
58. Scholdberg TA, Nechev LV, Merritt WK, Harris TM, Harris CM, Lloyd RS, Stone MP. Mismatching of a site specific major groove (2S,3S)-N6-(2,3,4-trihydroxybutyl)-2'-deoxyadenosyl DNA adduct of butadiene diol epoxide with deoxyguanosine: formation of a dA(anti).dG(anti) pairing interaction. *Chem. Res. Toxicol* 2005;18:145–153. [PubMed: 15720118]

Figure 1. UV (left panel) and MS³ spectra (right panel) of synthetic compounds **1** (A), **2** (B), **3** (C) and **4** (D).

Figure 2. ¹H-NMR (A), HMBC (B and D) and phase sensitive HSQC spectra (C) of compound **3** (Bruker 700 MHz) (Inset: enlarged area of 3.2 – 4.3 ppm).

Figure 3. Molecular models of compounds **3b** (A), **4b** (B) and proposed intramolecular hydrogen bonding in **4b** (C). Selected interatomic distances for protons observed in NOESY spectra are indicated.

Figure 4. HPLC-UV analysis of pure standard of **3a** (A), pure standard of **4a** (B), and the reaction mixture following forced Dimroth rearrangement of **3a** (C).

Figure 5.

Formation of exocyclic DEB-dA adducts in DNA *in vitro* and *in vivo*: capillary HPLC-ESI⁺ MS/MS analysis of compounds **3** and **4** in enzymatic digests of calf thymus DNA treated with *R,R* DEB (A); *S,S* DEB (B); *meso* DEB (250 μ M DEB, 24 h at 37 °C) (C); Concentration-dependent formation of exocyclic DEB-dA adducts **3** and **4** in calf thymus DNA treated with 0 – 1 mM DEB (24 h at 37 °C) (D); and capillary HPLC-ESI⁺ MS/MS analysis of **3** and **4** in enzymatic digests of liver DNA from a B6C3F1 mouse exposed to 625 ppm butadiene for 2 weeks (E). No signals corresponding to **3** and **4** were observed in DNA digests from control animals.

Scheme 1.

Formation of **1**, **2**, **3**, and **4** upon coupling of 6-Cl-purine-2'-deoxyriboside with N-fmoc-1-amino-2-hydroxy-3,4-epoxybutane.

Scheme 2.

Stereospecific synthesis of compound **2a**.

a) 1 eq. BzNH₂, p-xylene, reflux, 3 h; b) LiAlH₄, THF, 12 h; c) H₂, 10% Pd-c, 55°C, 24 h; d) 2'-deoxyinosine, DMSO, DIPEA, PyBOP, 55°C, 3 d.

Scheme 3.
Protonated and deprotonated forms of **3** and **4**.

Scheme 4.

Stereospecific synthesis of compounds **3a**, **3b**, **4a** and **4b**.

a) TMS-CN, Zn-I₂, reflux; b) i. LiAlH₄/Et₂O ii. aq. work up; c) 1R-endo,anti-(+)-3-bromocamphor-8-sulfonic acid ammonium salt, methanol; d) Aq., excess Ba(OH)₂; e) Fmoc-Cl, aq. dioxane, aq. Na₂CO₃, rt; f) i. mCPBA, CH₂Cl₂, rt, 18 h. ii. HPLC separation of diastereomers; g) 6-chloropurine-deoxyribose, DIPEA, DMSO, 37 °C, 3 d; h) 2'-deoxyinosine, PyBOP, DMSO, DIPEA, rt, 5 d; i) H₂O, rt, 15 h.

Scheme 5.
Dimroth rearrangement of compound **3a** to form **4a**.

Scheme 6.

Formation of stereoisomers of **3** and **4** in animals treated with 1,3-butadiene.

Scheme 7.

Proposed mechanism of the formation of **3a** and **4a** in DEB-treated DNA under physiological conditions.

Scheme 8.

Pericyclic rearrangement for interconversion of **4a** and **3a** under physiological conditions.

Chart 1.

Chart 2.

Table 1

pH dependence of the UV absorbance spectra of exocyclic DEB-dA adducts

Compound	UV _{max} , nm		
	0.1M HCl	Water	0.1M NaOH
2a	268	274	274
2b	268	274	274
2c	268	274	274
3a	264	264	265
3b	264	265	267
4a	264	265	266
4b	264	265	267